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Background. Collagen-induced arthritis (CIA), a murine experimental disease model induced by immunization with type II
collagen (CII), is used to evaluate novel therapeutic strategies for rheumatoid arthritis. Adult stem cell marker Musashi-1 (Msi1)
plays an important role in regulating themaintenance and differentiation of stem/precursor cells.The objectives of this investigation
were to perform amorphological study of the experimental CIAmodel, evaluate the effect of TNF𝛼-blocker (etanercept) treatment,
and determine the immunohistochemical expression of Msi1 protein. Methods. CIA was induced in 50 male DBA1/J mice for
analyses of tissue and serum cytokine; clinical and morphological lesions in limbs; and immunohistochemical expression of Msi1.
Results. Clinically, TNF𝛼-blocker treatment attenuated CIA on day 32 after immunization (𝑃 < 0.001). Msi1 protein expression was
significantly higher in joints damaged byCIA than in those with no lesions (𝑃 < 0.0001) andwas related to the severity of the lesions
(Spearman’s rho = 0.775, 𝑃 = 0.0001). Conclusions. Treatment with etanercept attenuates osteoarticular lesions in the murine CIA
model. Osteoarticular expression of Msi1 protein is increased in joints with CIA-induced lesion and absent in nonlesioned joints,
suggesting that this protein is expressed when the lesion is produced in order to favor tissue repair.
1. Introduction
Collagen-induced arthritis (CIA), a murine experimental
diseasemodel induced by immunizationwith type II collagen
(CII), shares a number of clinical, histopathological, and
immunological features with rheumatoid arthritis (RA) [1].
Although its etiology is unknown, the initial stages of RA and
CIA involve multiple steps that can be divided into two main
phases: the initiation and establishment of autoimmunity to
collagen-rich joint components, and later events associated
with progressively destructive inflammatory processes [1–4].
Progression of the autoimmune response involves the
development of autoreactive Th1 and Th17 cells, their entry
into the joint tissues, and the subsequent recruitment of
inflammatory cells via multiple mediators [4]. The chronic
nature of the inflammatory process in RA suggests a distur-
bance of immune regulation in the joint, probably caused by
an excessive inflammatory response along with deficiency in
the mechanisms controlling the immune response. Available
therapies are based on immunosuppressive agents that inhibit
the inflammatory component of RA and either reduce the
relapse rate or delay disease onset. However, they have
Hindawi Publishing Corporation
BioMed Research International
Volume 2015, Article ID 681456, 9 pages
http://dx.doi.org/10.1155/2015/681456
2 BioMed Research International
multiple effects, some of which are undesirable, and in the
long term they do not prevent progressive clinical disability
[5].
Tumor necrosis factor alpha (TNF-𝛼) is a proinflamma-
tory cytokine expressed in the pannus of the inflamed joint
in RA [6–9]. TNF𝛼-blocker drugs are among those currently
used for the treatment of RA. The subcutaneous admin-
istration to RA patients of the TNF-𝛼 receptor antagonist
etanercept (50mg once a week) was found to induce clinical
improvements not observed with the drugs previously used
in this disease [10, 11]. In addition, the beneficial effects of
TNF𝛼-blocker therapy have been demonstrated by various
research groups in a mouse model of CIA [12–17].
The adult stem cell marker Musashi-1 (Msi1) is an RNA-
binding protein of 362 amino acids with two ribonucle-
oprotein motifs (RBD1 and RBD2) [18] of 39 kDa molec-
ular weight. Msi1 is associated with the maintenance and
asymmetric cell division of neural and epithelial progenitor
cells [19]. It is expressed in various epithelial stem cells and
plays an important role in regulating the maintenance and
differentiation of stem/precursor cells [20, 21]. Msi1 is known
to regulate progenitor cell function through the posttran-
scriptional regulation of its target RNA [20]. Msi1 also acts
as an important positive regulator of cell proliferation and
inhibitor of apoptosis by reducing Notch-1 expression [22].
Modulation of Msi1 immunohistochemical expression
has been identified in amurinemodel of inflammatory colitis
[23], and it has been speculated that Msi1 might promote
cell proliferation by accelerating the cell cycle in neoplastic
cells [24], suggesting a role for this protein in tissue repair
in different processes and as a potential therapeutic target in
regenerative medicine.
The objectives of this study were to morphologically ana-
lyze the experimental collagen-induced arthritis model, to
evaluate the effect of treatment with a TNF𝛼-blocker (etaner-
cept), and to determine the immunohistochemical expression
of Msi1 protein.
2. Material and Methods
2.1. Induction and Treatment of Collagen-Induced Arthritis
(CIA). CIA was induced in 50 male DBA1/J mice (7 to
10 weeks old; Jackson Laboratories, Bar Harbor, ME) by
subcutaneous injection into the tail base with 200 𝜇g bovine
CII (Sigma, St. Louis, MO) at day 0 and with 100 𝜇g CII at day
21, both emulsified in complete Freund’s adjuvant containing
200𝜇g Mycobacterium tuberculosis H37 RA (Difco, Detroit,
Michigan). Treatment consisted of the intraperitoneal injec-
tion of 2mg of etanercept (Enbrel, Wyeth Europa Ltd., UK;
E-group) or of phosphate-buffered saline (PBS; untreated
control, C-group) once a week for four weeks (on days 25,
32, 39, and 46) starting at day 25 after immunization, when
all mice showed established arthritis (clinical score >2). Mice
were evaluated by two independent blinded examiners every
other day andmonitored for signs of arthritis onset according
to the following clinical score: grade 0, no swelling; grade 1,
slight swelling and erythema; grade 2, moderate swelling and
edema; grade 3, extreme swelling and pronounced edema;
or grade 4, joint rigidity. Each limb was graded, giving a
maximum possible score of 16 per animal. Paw swelling was
assessed bymeasuring the thickness of the affected hind paws
with 0 to 10mm calipers (on days 25, 32, 39, 46, and 53). All
experiments were performed in a European Union-certified
laboratory following national guidelines for the ethical care
of animals (RD 53/2013, EU Directive 63/2010).
2.2. Cytokine Determination. Protein extracts were isolated
by homogenization of joints (50mg tissue/mL) in 50mM
Tris-HCl, pH 7.4, with 0.5mMDTT and proteinase inhibitor
cocktail (10 𝜇g/mL, Sigma) for cytokine determination in
joints, and serum samples were collected at the disease peak
(day 40); serum and joint cytokine and chemokine levels
were determined by specific sandwich ELISAs using capture/
biotinylated detection Abs from BD Pharmingen (San Diego,
CA) according to the manufacturer’s recommendations.
2.3. Histopathological Study. For the histopathological study,
mice were anesthetized with ether and sacrificed by cervical
dislocation at day 15 (𝑛 = 20), 21 (𝑛 = 20), or 28 (𝑛 = 10)
after commencement of treatment with etanercept or PBS
(i.e., days 39, 46, and 53 after immunization).They were fixed
in 10% buffered formalin for 24 hours, decalcified withDecal-
cifier I, containing formaldehyde (10% w/v), formic acid (8%
w/v), and methanol (1% w/v) (Surgipath softener I Europe
Ltd., Peterborough, UK) for 24 h in oven at 37∘C. Next, the
four limbs were sectioned longitudinally, dehydrated with
alcohol, and embedded in paraffin in an automatic tissue
processor Excelsior ES (Thermo Scientific, CA, USA); 4𝜇m
sections were stained with hematoxylin and eosin (H&E)
or Masson trichrome stain. Histopathological changes were
scored in a blindedmanner based on cell infiltration, cartilage
destruction, and bone erosion parameters as previously
described [25]. Cell infiltration was scored on a scale of 0–
3 according to the number of affected joints (0: none, 1: <2, 2:
3–5; 3: >5 joints), and the amount of inflammatory cells in the
synovial cavity (exudate) and synovial tissue (infiltrate) was
also recorded. Cartilage destruction was graded on a scale
of 0–3, ranging from the appearance of dead chondrocyte
(empty lacunae) to complete loss of articular cartilage. Bone
erosions were graded on a scale of 0–3, ranging from normal
bone appearance to fully eroded cortical bone structure in
patella and femur condyle. Pannus and involvement of the
bone marrow and/or soft tissue were treated as dichotomous
variables (present or absent).
2.4. Immunohistochemical Analysis. Decalcified andparaffin-
embedded sectionswere dewaxed, hydrated, and heat-treated
in 1mM EDTA pH 8 in an antigen retrieval PT module
(Thermo Fisher Scientific Inc., Waltham, MA) at 95∘C for
20min. Sections were incubated for 16 h at 4∘C with the
prediluted polyclonal antibody against Musashi-1 (Sigma-
Aldrich, Barcelona, Spain) at 1 : 100 dilution to identify cel-
lular expression. An automatic immunostainer (Autostainer
480,Thermo Fisher Scientific Inc.) was used for the immuno-
histochemical study, applying the peroxidase conjugated
micropolymer method and developing with diaminoben-
zidine (Ultravision Quanto, Master Diagnóstica, Granada,
Spain). Expression was assessed semiquantitatively on a scale
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Table 1: Comparative study of morphological variables in DBA1/J mice after 21 and 28 days of starting treatment.
Variables Control group Etanercept group
∗
𝑃 values† Control group Etanercept group∗ 𝑃 values†
Day 46 after immunization Day 53 after immunization
Number of joints 2.1 ± 0.69 1.8 ± 0.88 0.412 2.45 ± 1.01 1.9 ± 0.56 0.006
Pannus 1 ± 0.21 0.9 ± 0.35 0.449 0.7 ± 0.31 1 ± 0 0.467
B & C injury 1.8 ± 0.71 1.3 ± 0.78 0.278 2 ± 0.94 1.55 ± 0.68 0.045
Inflammation 1.5 ± 1 1.3 ± 1 0.661 1.55 ± 0.83 1.1 ± 0.69 0.036
Bone marrow 0.6 ± 0.47 0.5 ± 0.39 0.613 0.55 ± 0.42 0.55 ± 0.43 0.930
Soft tissue 0.15 ± 0.15 0.2 ± 0.21 0.557 0.35 ± 0.31 0.15 ± 0.15 0.010
Mean score 6.85 ± 2.95 5.8 ± 3.37 0.469 8 ± 3.55 6 ± 2.12 0.011
Values are expressed as mean ± standard deviation; ∗treatment: etanercept 2mg/week; B & C: bone and cartilage; †Student’s 𝑡-test. See Figure 3 for details.
of 0 to 3 (0: absence, 1: mild [<10% positive cells], 2: moderate
[10 to 25%], 3: intense [>25%] in bone tissue, hyaline
cartilage, joint capsule, synovium, ligaments, striated muscle
cells, endothelial cells, and adipocytes). The variables were
subsequently categorized in two groups (presence/absence of
osteoarticular lesion), calculating the total Msi1 expression
score for each group.
2.5. Statistical Analysis. SPSS 20.0 (IBM Inc., Chicago, IL)
was used for the statistical analysis. The normality of the
distribution of variables was examined with the one-dimen-
sional Kolmogorov-Smirnov test. Results were expressed as
mean ± standard deviation for normally distributed contin-
uous variables and frequencies for categorical variables. The
bivariate tests and Spearman correlation coefficient used are
reported in the table footnotes. A𝑃 value of 0.05was accepted
as the statistical significance threshold.
3. Results
The clinical score was significantly attenuated in mice with
CIA after 1 week of systemic treatment with the TNF𝛼-
blocker etanercept (𝑃 < 0.001) in comparison to untreated
mice (Figure 1). This treatment also significantly reduced
serum and joint tissue levels of Th1-mediated proinflamma-
tory cytokines and increased levels of the anti-inflammatory
cytokine IL10 (Figure 2).
The histopathological study demonstrated a CIA induc-
tion efficiency of 95% in DBA1/J mice, which showed pannus
formation and chronic lymphocytic/monocytic inflamma-
tory infiltrate with acute phenomena (neutrophil leukocytes)
that involved the joint soft tissues (Figure 3). These mice
also showed the presence of necrotic cells in the intra-
articular space, secondary destruction of the joint cartilage,
and increased destruction of bone tissue through osteoclastic
activation, with sporadic involvement of the bone medulla
and extension of inflammatory infiltrate into periarticular
soft tissues (Figure 3). Injection of etanercept in CIA mice
moderately decreased most of the histopathological signs
of arthritis, especially after four weeks of treatment (day
53 after immunization, Table 1). No significant differences
in morphologic variables were observed between untreated
and etanercept-treated mice after three weeks of treatment
























Figure 1: TNF𝛼-blocker administration attenuates clinical CIA.
Clinical scores in mice with CIA intraperitoneally treated from day
25 after immunization with PBS (control, C-group, closed squares)
or TNF𝛼-blocker (2mg/week, E-group, open circles) once per week
for four weeks. Values are the mean ± SD of 20 mice per group.
Differences were significant at 𝑃 < 0.001 (asterisks) for E-group
versus C-group at indicated time points.
of the histopathological results according to the absence or
presence of lesions (0 = absence, 1 = presence) showed that the
etanercept treatment attenuated the progression of clinical
inflammation in the limbs (mean of 0.55 in the etanercept
group versus 0.85 in control group after 21 days of treatment;
𝑃 < 0.003, Student’s 𝑡-test).
The immunohistochemical expression of Msi1 was then
investigated in different tissue components in the joints of
untreated and etanercept-treated CIA mice. Msi1-specific
stainingwasmainly observed at nuclear level in chondrocytes
and spindle-shaped mesenchymal cells of the articular cap-
sule and ligaments (Figure 4). Scant expression was detected
in osteocytes, synoviocytes, or inflammatory cells in articular
or periarticular lesions or inmedullary bone tissue (Figure 4).
No Msi1 expression was observed in striated muscle cells or
mature adipocytes (Figure 4).
Quantitative analysis of Msi1 expression in the different
groups revealed significantly higher expression in joints with
CIA-induced articular lesions than in joints without lesions
(𝑃 < 0.0001, Student’s 𝑡-test, Figure 4). Significant positive


















































Figure 2: TNF𝛼-blocker administration decreases inflammatory response in CIA. DBA1/J mice with established CIA (day 25 after
immunization) were intraperitoneally injected with PBS (closed columns) or anti-TNF𝛼 (2mg/week, open columns) once per week. Systemic
and local expression of inflammatory mediators was assayed in protein extracts from joints of hind limbs (a) and sera (b) isolated at day 40
after immunization; 𝑛 = 3 to 4 mice/group. ∗𝑃 < 0.01 versus controls.
Table 2: Spearman’s correlation coefficient (rho) for Msi1 immuno-
histochemical expression between different articular components.
Cartilage Capsule Ligament Synovium
Cartilage 1 0.225∗ 0.308∗∗ 0.556∗∗
Capsule 1 0.663∗∗ 0.389∗∗
Ligament 1 0.260∗
Synovium 1
∗Significant correlation at 0.05 (bilateral); ∗∗significant correlation at 0.01
(bilateral).
correlations were also observed between the presence of
osteoarticular lesion and Msi1 expression (Spearman’s rho:
0.775, 𝑃 = 0.001) and among Msi1 expression levels at the
different sites (capsule, ligament, synovium, and cartilage)
(Table 2). However, although a slight decrease inMsi1 expres-
sionwas observed in affected joints in etanercept-treated CIA
mice, no statistically significant differences in articular Msi1
expression were found between PBS-treated and etanercept-
treated CIA mice after three (𝑃 = 0.449, Student’s 𝑡-test)
or four (𝑃 = 0.080, Student’s 𝑡-test) weeks of treatment
(Figure 5).
4. Discussion
This study confirmed that TNF𝛼-blocker treatment attenu-
ates CIA-induced histopathological lesions in the joints of
CIA-susceptible DBA1/J mice and revealed, for the first time,
a more intense expression of Msi1 protein in cartilage, liga-
ment, articular capsule, mesenchymal cells, and osteocytes in
CIA-lesioned versus nonlesioned joints.
Although no animal model of RA completely replicates
the human disease, the CIA model employed in this study
has been widely used for the testing and development of RA
therapies [26–29]. In fact, the CIA induction rate was very
high (>95%) in the present study. Likewise, DBA1/Jmicewere
selected rather than other animals (e.g., rats) [30] because
better outcomes are obtained in genetically modified strains
and the arthritis is more similar to human RA [31, 32]. Major
insights into the molecular mechanisms of inflammatory
arthritis recently emerged from the study of murine models
of RA-like disease using genetically deficient or transgenic
mice or a combined murine model (K/BxAg7) that sponta-
neously develops both RA-like disease and atherosclerosis
[33]. However, these studies may be limited by the differences
betweenhuman andmurine immune systems. Current efforts
to develop an animal model that utilizes human immune
cells will allow study of their function in the initiation and
propagation of inflammatory arthritis [34].
RA is a chronic debilitating disease in which the induc-
tion of autoimmunity to collagen-rich joint components
underlies the onset of the disease and the subsequent destruc-
tive inflammatory process. Progression of the autoimmune
response implies the development of autoreactive Th1 (pro-
ducing IFN𝛾 and TNF𝛼) and Th17 (producing Th17) cells,
their entry into articular tissue, and the release of proin-
flammatory cytokines and chemokines, which promote
macrophage and neutrophil infiltration and activation [3, 35,
36]. Excessive production by infiltrating inflammatory cells
of inflammatory cytokines, free radicals, and extracellular
matrix–degrading enzymes plays a critical role in cartilage
damage and bone erosion. A desirable therapeutic approach
would be to prevent the activation of inflammatory and









Figure 3: Morphological features of articular lesion in CIA model in DBA1/J mice. (a): (A) Unaffected joint. (B) Pannus. (C) Synovial
hyperplasia with chronic inflammatory infiltrate. (D) Hyaline cartilage surrounded by spindle-shaped mesenchymal cells. (E) Bone
destruction mediated by osteoclast activation. (F) Partial destruction of articular cartilage. Bar 100 𝜇m (Masson’s trichrome, original
magnification ×20). (b): (A) Limb without joint lesions. (B) Partial response to etanercept with persistence of pannus (E-group). (C) Intense
joint lesion with pannus and chronic inflammatory infiltrate in articular cavity and partial destruction of bone tissue (C-group) (Masson’s
trichrome, original magnification ×4).
autoimmune components. Our group previously demon-
strated that 5-aminoisoquinolinone, a poly(ADP-ribose) pol-
ymerase-1 inhibitor, significantly reduces the incidence and
severity of established CIA, completely abrogating joint
swelling and cartilage/bone destruction by downregulating
inflammation and the Th1 response [37]. The administration
of TNF𝛼-blocker to arthritic mice decreases the CII-specific
Th1-mediated cytokine response through direct action on the
synovium [38–40]. The present results confirm that treat-
ment of established CIA with etanercept reduces articular
levels of Th1 cytokines (IFN𝛾 and TNF𝛼) and inflammatory
chemokines. This effect may be directly related to a decrease
in inflammatory infiltrates in the joints of etanercept-treated
mice. However, the fact that levels of the anti-inflammatory
cytokine IL10 were increased by the injection of etaner-
cept supports the proposition that this TNF𝛼-blocker also
promotes a bias towards a regulatory/anti-inflammatory
response.
Etanercept and other blockers of TNF𝛼 action (inflix-
imab, adalimumab, golimumab, and certolizumab pegol)
offer specific anti-cytokine therapies but induce a general
immunosuppressive action. Etanercept has become the drug
of choice for late stage RA with reasonable safety, and the
present study confirms that it attenuates the progression of
histopathological lesions, as demonstrated in CIA murine
models [12–17] and in the clinical setting [41, 42]. However,






Figure 4: Immunohistochemical expression of Musashi-1 (Msi1) in CIA model in DBA1/J mice. (a): (A) Scant Msi1 expression was
detected in chondrocytes, synoviocytes, and inflammatory cells in articular or periarticular lesions or in medullary bone tissue in joints
with no morphological changes. (B) Nuclear expression of Msi1 in mesenchymal cells, articular capsule, and articular cartilage. Bar
200 𝜇m (micropolymer peroxidase-based method, original magnification ×4). (b): (A) Very scant nuclear Msi1 expression in joint with no
morphological changes (E-group). (B), (C), and (D)ModerateMsi1 expression inmesenchymal cells, articular capsule, and articular cartilage
in CIA-lesioned joints (C-group) (micropolymer peroxidase-based method, original magnification ×20).
etanercept must be taken frequently, it is expensive, and it
increases the susceptibility of the patient to infections [43].
The present study provides the first report on the osteoar-
ticular expression of Msi1. No direct evidence has been pub-
lished to date linking Msi1 with osteoarticular regeneration.
Msi1 is involved in the regulation of self-renewal of stem
cells. In order to maintain their unlimited capacity to divide,
stem cells require controlled temporal and spatial protein
expression. The Musashi family of RNA-binding proteins
exerts this essential translational control (via repression and
activation) in order to regulate multiple stem cell populations
[44], and Msi1-dependent posttranscriptional enhancement
of m-Numb is crucial in epithelial regeneration [45]. Nuclear
expression of Msi1 was more intense in the presence of
osteoarticular lesion and was not observed in nonlesioned
joints, with or without anti-TNF𝛼 treatment. In previous
studies on fractures in rats, we observed a marked increase
in Msi1 expression in the reparative fibrocartilaginous tissue
of the fracture callus (data not shown). Msi1 protein regulates
the transcription and differentiation of mesenchymal stem
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Figure 5: Representative immunohistochemical expression of Msi1 in E-group versus C-group in CIA model (DBA1/J mice). (a) Moderate
Msi1 expression in mesenchymal cells, articular capsule, and articular cartilage in CIA-lesioned joints at 21 days after treatment (E-group);
(b) moderate Msi1 expression in CIA-lesioned joints at 21 days after treatment (C-group); (c) joint Msi1 expression at 28 days after treatment
(E-group); (d) joint Msi1 expression at 28 days after treatment (C-group) (micropolymer peroxidase-based method, original magnification
×20).
cells; therefore, its presence in these tissues suggests its
involvement in tissue repair and regeneration processes.
Our novel findings on the expression of Msi1 in osteoar-
ticular tissues may support the participation of this protein
in tissue regeneration processes and suggest the involvement
of adult mesenchymal stem cells in the repair of these tissues.
These data may serve as a basis for future investigations on
repair processes in cartilaginous and bone tissues.
5. Conclusions
Treatment with etanercept attenuates the osteoarticular le-
sions in the murine model of CIA.The osteoarticular expres-
sion of Msi1 protein is increased in joints with CIA-induced
lesion and absent in nonlesioned joints, suggesting that this
protein is expressed when the lesions are produced in order








TNF𝛼: Tumor necrosis factor alpha.
Conflict of Interests
The authors do not have any financial interests, either directly
or indirectly, in the products or information listed in the
paper.
Authors’ Contribution
Francisco O’Valle, Pedro Hernandez-Cortes, Elena Gonz-
alez-Rey, and Mario Delgado conceived, designed, and per-
formed the mouse model, coordinated in the study, and
drafted the paper. Magdalena Peregrina, Pablo Galindo-
Moreno,Maria Roman,Miguel Padial-Molina, and Francisco
Mesa analyzed the clinical and biochemical data and drafted
the paper. Vicente Crespo, Jose Aneiros Fernandez, and
David Aguilar analyzed the morphology and immunohisto-
chemical data. All authors read and approved the final version
of this paper.
Acknowledgments
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